Recent Decrease in Excess Risk of All-Cause Mortality in ESRD

This article originally appeared here.
Share this content:
Recent Decrease in Excess Risk of All-Cause Mortality in ESRD
Recent Decrease in Excess Risk of All-Cause Mortality in ESRD

FRIDAY, Dec. 15, 2017 (HealthDay News) -- Among individuals with end-stage renal disease (ESRD), there was a decrease in the excess risk of all-cause mortality from 1995 to 2013, according to a study published online Dec. 14 in the Clinical Journal of the American Society of Nephrology.

Bethany J. Foster, M.D., from the Montreal Children's Hospital Research Institute, and colleagues calculated relative excess risks to examine the correlation between advancing calendar time and all-cause mortality. Data from 1,938,148 children and adults with ESRD from 1995 to 2013 were included.

The researchers observed variation in the adjusted relative excess risk per five-year increment in calendar time from 0.73 for 0- to 14-year-olds to 0.88 for ≥65-year-olds, meaning that for any five-year interval between 1995 and 2013, there was a 12 to 27 percent decrease in the excess risk of ESRD-related death. Over time there were decreases in excess mortality for all ages and both during treatment with dialysis and with a functioning kidney transplant. The youngest individuals with a functioning kidney transplant had the largest relative improvements; the oldest individuals had the greatest absolute decreases in excess ESRD-related mortality.

"The excess risk of all-cause mortality among people with ESRD, over and above the risk in the general population, decreased significantly between 1995 and 2013 in the United States," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease



Sign up for myCME e-newsletters


More in Home

FDA Approves First Drug for Rare Form of Rickets

FDA Approves First Drug for Rare Form of ...

Crysvita approved for adults and children ages 1 year and older with x-linked hypophosphatemia

High FGF-23 Linked to Recurrent Cardiac Events After ACS

High FGF-23 Linked to Recurrent Cardiac Events After ...

FGF-23 in top quartile independently linked to greater risk of CV death, heart failure hospitalization

Medical Cannabis Not Recommended for Sleep Apnea

Medical Cannabis Not Recommended for Sleep Apnea

American Academy of Sleep Medicine says evidence insufficient to recommend cannabis for apnea

is free, fast, and customized just for you!

Already a member?

Sign In Now »